Abstract
Ovarian clear cell adenocarcinoma (OCCA) is a unique biological subtype of epithelial ovarian cancer, with a similar gene profile to renal cell carcinoma (RCC). Sunitinib is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with proven antitumor activity in RCC and a rational biological option for treatment of OCCA. A 60-year-old woman presented with recurrent and refractory stage IA OCCA, after 9 years of remission. Sunitinib was initiated as fifth-line chemotherapy, associated with cystic degeneration of liver metastasis and a short downward trend in her CA125 level. Recurrent and refractory OCCA may respond to Sunitinib. Clinical trials are needed to objectively confirm these findings, as benefit may be limited in patients with extensively pretreated tumors.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 934-936 |
| Number of pages | 3 |
| Journal | International Journal of Gynecological Cancer |
| Volume | 18 |
| Issue number | 5 |
| DOIs | |
| State | Published - Sep 1 2008 |
| Externally published | Yes |
Keywords
- Angiogenesis
- Ovarian clear cell adenocarcinoma
- Sunitinib
- VEGF
ASJC Scopus subject areas
- Cancer Research
- Obstetrics and Gynecology
- Oncology